Cancer drugs rediscovered by Agemica platform

 Agemica's platform is able to analyze genomics data of different diseases and suggest potential therapies from compounds in our database that have a higher probability of success. We have applied Agemica's platform on a database of cancers covering 34 types and 175 sub-types and asked the platform to rank order 700,000 compounds in the database blinded. In the above 17 cancers, the platform has rediscovered standards of care.

We have predicted combinations with the above drugs and multiple other compound/antibody combination therapies that have potential pan-anti-cancer efficacy. 

The technology is experimentally validated extensively on pre-clinical models for childhood sarcoma, pancreatic cancer, and malaria. As well as differentiation therapy of leukemia cells to normal healthy cells and in the area of cellular reprogramming for enhancing cloning animals and stem cell differentiation. It had 96% accuracy on predicting novel compound candidates for sarcoma which was experimentally validated.